Procter & Gamble vs Colgate-Palmolive: Two Consumer Giants, Two Strategies, One Invests, Other Optimizes

P&G reported fiscal Q3 revenue of $21.23B (+7.4% YoY) and core EPS of $1.59, beating consensus for the fourth straight quarter, but core gross margin fell 100 bps due to tariffs and mix; tariffs are estimated to cost ~$400M after-tax and it now guides to the low end of the $6.83–$7.09 core EPS range. Colgate delivered $5.32B revenue (+8.4% YoY) with Latin America (+14.8%) and Europe (+11.9%) strong, but North America slid 1.8% on a 3.2% volume decline amid heavy resets/couponing, while restructuring (SGPP) expands to $350–$550M cumulative pre-tax charges targeting $200–$300M annual savings. Overall, both beats are tempered by tariff/margin pressure for P&G and a key North America execution risk plus restructuring costs for Colgate—suggesting a cautious near-term setup.

Analysis

The market is treating staples as one trade, but the dispersion is now driven by earnings quality, not just defensive beta. PG has the cleaner near-term setup because broad-based growth can absorb input-cost noise better than a narrow geographic rebound story; however, the next leg depends on whether innovation-led mix can offset tariff/oil drag without another round of promo intensity. If that cost headwind shows up in the next two reporting cycles, the stock can still re-rate lower on margin risk even if revenue stays resilient.

CL looks like a classic self-help story that needs time, and that is exactly why it is vulnerable to disappointment over the next 1-3 months. The consensus may be underweighting how much of the apparent improvement is coming from higher-volatility regions and a premium pet franchise, while the U.S. business still depends on shelf resets and competitor couponing normalizing. Restructuring can lift 2027 earnings power, but it does not fix near-term share losses; if North America volumes stay negative, the market will eventually discount the savings plan as merely defensive.

Contrarian view: the cleanest trade is not to chase the turnaround narrative, but to own the company with more credible pricing power and less execution risk. The biggest falsifier for a PG-long/CL-short stance is a two-quarter streak of positive U.S. volume for CL plus stabilizing gross margin guidance; absent that, the relative-value spread should continue to favor PG. On the flip side, if oil-linked costs accelerate again, both names can de-rate together, so this is a spread trade, not a blanket staples bullish call.

Key Decisions for Investors

• Long PG / short CL for 1-3 months: target 5-8% relative outperformance in PG if CL North America remains weak and PG holds broad-based growth; stop if CL U.S. volumes turn positive for two straight quarters.
• Use PG as the defensive-staples core long on any 2-3% pullback tied to tariff or oil headlines; risk/reward is favorable because earnings quality is better than the headline multiple suggests, but trim if management re-anchors guidance back to the low end.
• Avoid adding CL until there is verifiable evidence that shelf resets are complete and couponing pressure eases; if you want exposure, wait for one quarter of positive North America volume before initiating.
• Monitor XLP relative to PG over the next earnings season; if PG continues to beat while peers absorb cost inflation, PG should outperform the basket by low single digits with lower drawdown risk than a standalone CL long.